PE20091107A1 - Nanoparticulas polimericas solidas funcionalizadas que comprenden epotilonas - Google Patents
Nanoparticulas polimericas solidas funcionalizadas que comprenden epotilonasInfo
- Publication number
- PE20091107A1 PE20091107A1 PE2008002025A PE2008002025A PE20091107A1 PE 20091107 A1 PE20091107 A1 PE 20091107A1 PE 2008002025 A PE2008002025 A PE 2008002025A PE 2008002025 A PE2008002025 A PE 2008002025A PE 20091107 A1 PE20091107 A1 PE 20091107A1
- Authority
- PE
- Peru
- Prior art keywords
- diona
- dihydroxy
- prop
- tetramethyl
- epotilones
- Prior art date
Links
- 239000002105 nanoparticle Substances 0.000 title abstract 4
- 229920000642 polymer Polymers 0.000 title abstract 2
- 239000007787 solid Substances 0.000 title 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 abstract 1
- 229920000615 alginic acid Polymers 0.000 abstract 1
- 229960001126 alginic acid Drugs 0.000 abstract 1
- 235000010443 alginic acid Nutrition 0.000 abstract 1
- 239000000783 alginic acid Substances 0.000 abstract 1
- 150000004781 alginic acids Chemical class 0.000 abstract 1
- 229920006317 cationic polymer Polymers 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229940039227 diagnostic agent Drugs 0.000 abstract 1
- 239000000032 diagnostic agent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000012874 electrostatic modification Methods 0.000 abstract 1
- 229920002674 hyaluronan Polymers 0.000 abstract 1
- 229960003160 hyaluronic acid Drugs 0.000 abstract 1
- HVOYZOQVDYHUPF-UHFFFAOYSA-N n,n',n'-trimethylethane-1,2-diamine Chemical compound CNCCN(C)C HVOYZOQVDYHUPF-UHFFFAOYSA-N 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920000728 polyester Polymers 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 229920002635 polyurethane Polymers 0.000 abstract 1
- 239000004814 polyurethane Substances 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
- A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0039—Coumarin dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0089—Particulate, powder, adsorbate, bead, sphere
- A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
- A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nanotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
SE REFIERE A NANOPARTICULAS POLIMERICAS CON POTENCIAL SUPERFICIAL CATIONICO QUE COMPRENDEN: A) UN POLIMERO CATIONICO TAL COMO UN POLIACRILATO MODIFICADO CON CATIONES POLI(N,N-DIMETILAMINOETILMETACRILATO) O POLI(N,N-DIMETILAMINOPROPILMETACRILAMIDA); B) UN POLIMERO POCO SOLUBLE EN AGUA TAL COMO UN POLIESTER, ACIDO ALGINICO, ACIDO HIALURONICO, POLIURETANOS, ENTRE OTROS; C) AGENTES DE DIAGNOSTICO Y EPOTILONAS TALES COMO (4S,7R,8S,9S,13E/Z,16S)-4,8-DIHIDROXI-16-(2-METILBENZOXAZOL-5-IL)-1-OXA-5,5,9,13-TETRAMETIL-7-(PROP-2-EN-1-IL)CICLOHEXADEC-13-EN-2,6-DIONA, (4S,7R,8S,9S,13E/Z,16S)-4,8-DIHIDROXI-16-(2-METILBENZOTIAZOL-5-IL)-1-OXA-5,5,9,13-TETRAMETIL-7-(PROP-2-EN-1-IL)-CICLOHEXADEC-13-EN-2,6-DIONA, (1S/R,3S,7S,10R,11S,12S,16R/S)-7,11-DIHIDROXI-10-(PROP-2-EN-1-IL)-3-(2-METILBENZOTIAZOL-5-IL)-8,8,12,16-TETRAMETIL-4,17-DIOXABICICLO[14,1,0]HEPTADECAN-5,9-DIONA, ENTRE OTROS. DONDE LA SUPERFICIE DE LAS NANOPARTICULAS HA SIDO SOMETIDA A UNA MODIFICACION ELECTROSTATICA CON UN AGENTE MODIFICADOR DE SUPERFICIE QUE CONTIENE UNA ESTRUCTURA CAPAZ DE RECONOCER EL BLANCO TAL COMO UN ANTICUERPO, UN POLIPEPTIDO, UNA MOLECULA DE ADN, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE CONTIENE DICHAS NANOPARTICULAS Y ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES NEOPLASICAS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102007059752A DE102007059752A1 (de) | 2007-12-10 | 2007-12-10 | Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20091107A1 true PE20091107A1 (es) | 2009-08-29 |
Family
ID=40409013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008002025A PE20091107A1 (es) | 2007-12-10 | 2008-12-09 | Nanoparticulas polimericas solidas funcionalizadas que comprenden epotilonas |
Country Status (7)
| Country | Link |
|---|---|
| AR (1) | AR069638A1 (es) |
| DE (1) | DE102007059752A1 (es) |
| PA (1) | PA8806901A1 (es) |
| PE (1) | PE20091107A1 (es) |
| TW (1) | TW200932220A (es) |
| UY (1) | UY31521A1 (es) |
| WO (1) | WO2009074274A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2462090T5 (es) | 2008-06-16 | 2017-07-12 | Pfizer Inc. | Nanopartículas poliméricas cargadas de fármaco y procedimientos de fabricación y uso de las mismas |
| US8613951B2 (en) | 2008-06-16 | 2013-12-24 | Bind Therapeutics, Inc. | Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same |
| ES2721850T3 (es) | 2008-06-16 | 2019-08-05 | Pfizer | Nanopartículas poliméricas terapéuticas que comprenden alcaloides vinca y procedimientos de fabricación y uso de las mismas |
| WO2010068866A2 (en) | 2008-12-12 | 2010-06-17 | Bind Biosciences | Therapeutic particles suitable for parenteral administration and methods of making and using same |
| JP2012512175A (ja) | 2008-12-15 | 2012-05-31 | バインド バイオサイエンシズ インコーポレイテッド | 治療薬を徐放するための長時間循環性ナノ粒子 |
| CN102361636A (zh) * | 2009-03-03 | 2012-02-22 | 公立大学法人横浜市立大学 | 氨基酸接合氰基丙烯酸酯聚合物粒子 |
| ES2721898T3 (es) | 2009-12-11 | 2019-08-06 | Pfizer | Formulaciones estables para liofilizar partículas terapéuticas |
| EP2515942B1 (en) | 2009-12-15 | 2020-02-12 | Pfizer Inc. | Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers |
| WO2011084521A2 (en) * | 2009-12-15 | 2011-07-14 | Bind Biosciences, Inc. | Therapeutic polymeric nanoparticles comprising epothilone and methods of making and using same |
| CA2799202C (en) | 2010-05-18 | 2016-07-05 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other diseases |
| WO2012026608A1 (en) * | 2010-08-24 | 2012-03-01 | Canon Kabushiki Kaisha | Polymeric particle and hydrophilic dye having a sulfonate group encapsulated within the particle |
| DK2895156T3 (da) | 2012-09-17 | 2019-07-15 | Pfizer | Fremgangsmåde til fremstilling af terapeutiske nanopartikler |
| JP6564369B2 (ja) | 2013-12-09 | 2019-08-21 | デュレクト コーポレイション | 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法 |
| SI3116547T1 (sl) | 2014-03-14 | 2019-08-30 | Pfizer, Inc. | Terapevtski nanodelci, ki obsegajo terapevtsko stredstvo, in postopek izdelave ter uporabe le-teh |
| WO2015181346A1 (en) * | 2014-05-30 | 2015-12-03 | AbbVie Deutschland GmbH & Co. KG | Highly drug-loaded poly(alkyl 2-cyanoacrylate) nanocapsules |
| DE102017100317A1 (de) | 2017-01-10 | 2018-07-12 | Friedrich-Schiller-Universität Jena | Nanostrukturiertes Trägersystem zum Gentransport |
| CN115078292B (zh) * | 2021-03-10 | 2025-02-11 | 北京大学 | 一种水性超分子粘附材料及其制备方法 |
| CN119768461A (zh) * | 2022-08-22 | 2025-04-04 | 爱克发-格法特公司 | 近红外和红光吸收复合树脂颗粒 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US262030A (en) | 1882-08-01 | Wash-stand | ||
| US252028A (en) | 1882-01-10 | Alonzo s | ||
| US258286A (en) | 1882-05-23 | Fruit-drier | ||
| US4774339A (en) | 1987-08-10 | 1988-09-27 | Molecular Probes, Inc. | Chemically reactive dipyrrometheneboron difluoride dyes |
| CA2032169A1 (en) * | 1989-05-04 | 1990-11-05 | Steven Kornguth | Method for localization and treatment of tumors and complexes therefor |
| US5366860A (en) | 1989-09-29 | 1994-11-22 | Applied Biosystems, Inc. | Spectrally resolvable rhodamine dyes for nucleic acid sequence determination |
| US5433896A (en) | 1994-05-20 | 1995-07-18 | Molecular Probes, Inc. | Dibenzopyrrometheneboron difluoride dyes |
| US5227487A (en) | 1990-04-16 | 1993-07-13 | Molecular Probes, Inc. | Certain tricyclic and pentacyclic-hetero nitrogen rhodol dyes |
| US5274113A (en) | 1991-11-01 | 1993-12-28 | Molecular Probes, Inc. | Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates |
| US5248782A (en) | 1990-12-18 | 1993-09-28 | Molecular Probes, Inc. | Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes |
| US5187288A (en) | 1991-05-22 | 1993-02-16 | Molecular Probes, Inc. | Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis |
| DE4138042C2 (de) | 1991-11-19 | 1993-10-14 | Biotechnolog Forschung Gmbh | Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel |
| FR2684103B1 (fr) | 1991-11-22 | 1994-09-02 | Centre Nat Rech Scient | Nouveaux composes a structure guanidique et composition pharmaceutique les contenant. |
| DE4445065A1 (de) | 1994-12-07 | 1996-06-13 | Diagnostikforschung Inst | Verfahren zur In-vivo-Diagnostik mittels NIR-Strahlung |
| JP4183099B2 (ja) | 1995-11-17 | 2008-11-19 | ゲゼルシャフト・フュア・ビオテヒノロジッシェ・フォルシュング・ミット・ベシュレンクテル・ハフツング（ゲー・ベー・エフ） | エポチロンｃおよびｄ、製造法ならびに組成物 |
| US6204388B1 (en) | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
| US6380394B1 (en) | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
| DE19728914A1 (de) | 1997-07-07 | 1999-01-14 | Basf Ag | Metallisch gefärbte Polyamide |
| US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
| WO1999007692A2 (de) | 1997-08-09 | 1999-02-18 | Schering Aktiengesellschaft | Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung |
| WO1999018934A1 (en) * | 1997-10-09 | 1999-04-22 | Vanderbilt University | Micro-particulate and nano-particulate polymeric delivery system |
| US6320045B1 (en) | 1997-12-04 | 2001-11-20 | Bristol-Myers Squibb Company | Process for the reduction of oxiranyl epothilones to olefinic epothilones |
| FR2775187B1 (fr) | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
| DE19820599A1 (de) | 1998-05-08 | 1999-11-11 | Biotechnolog Forschung Gmbh | Epothilonderivate, Verfahren zu deren Herstellung und deren Verwendung |
| AU4775299A (en) | 1998-06-22 | 2000-01-10 | Nicolaou, Kyriacos Costa | Desmethyl epothilones |
| SE517641C2 (sv) | 1998-07-02 | 2002-07-02 | Sca Hygiene Prod Ab | Förfarande för att framställa ett materialskikt med barriärflikar samt ett ytskikt med sådana barriärflikar |
| JP2000095758A (ja) | 1998-09-18 | 2000-04-04 | Schering Ag | 近赤外蛍光造影剤および蛍光造影方法 |
| EP1140944B1 (en) | 1998-12-22 | 2003-08-27 | Novartis AG | Epothilone derivatives and their use as antitumor agents |
| DE19908763A1 (de) | 1999-02-18 | 2000-08-24 | Schering Ag | Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung |
| DE19908760A1 (de) | 1999-02-18 | 2000-08-24 | Schering Ag | Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung |
| SK11852001A3 (sk) | 1999-02-18 | 2002-04-04 | Schering Aktiengesellschaft | Deriváty epotiólonu, spôsoby ich výroby a ich farmaceutické použitie |
| DE19907588A1 (de) | 1999-02-22 | 2000-08-24 | Biotechnolog Forschung Gmbh | C-21 Modifizierte Epothilone |
| IL144590A0 (en) | 1999-03-29 | 2002-05-23 | Bristol Myers Squibb Co | A process for the preparation of epothilone derivatives |
| AR023792A1 (es) | 1999-04-30 | 2002-09-04 | Bayer Schering Pharma Ag | Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos |
| CA2425620A1 (en) | 1999-10-08 | 2001-04-19 | The Scripps Research Institute | 13-alkyl epothilone derivatives |
| EP1259490A2 (en) | 2000-03-01 | 2002-11-27 | Sloan Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US6518421B1 (en) | 2000-03-20 | 2003-02-11 | Bristol-Myers Squibb Company | Process for the preparation of epothilone analogs |
| US6593115B2 (en) | 2000-03-24 | 2003-07-15 | Bristol-Myers Squibb Co. | Preparation of epothilone intermediates |
| DE10020517A1 (de) | 2000-04-19 | 2001-10-25 | Schering Ag | Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung |
| US20020045609A1 (en) | 2000-05-26 | 2002-04-18 | Gary Ashley | Epothilone derivatives and methods for making and using the same |
| US20020137152A1 (en) | 2000-07-25 | 2002-09-26 | Daniel Santi | Fermentation process for epothilones |
| UA75365C2 (en) | 2000-08-16 | 2006-04-17 | Bristol Myers Squibb Co | Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon |
| CA2425828A1 (en) | 2000-10-13 | 2002-04-18 | The University Of Mississippi | Synthesis of epothilones and related analogs |
| ATE349412T1 (de) | 2000-10-16 | 2007-01-15 | R & D Biopharmaceuticals | Epothilon-synthesebausteine i: unsymmetrisch substituierte acyloine und acyloinderivate, verfahren zu deren herstellung sowie deren verwendung zur herstellung von epothilonen und epothilonderivaten |
| WO2002080846A2 (en) | 2001-04-03 | 2002-10-17 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
| DE102005041860A1 (de) * | 2005-09-02 | 2007-03-08 | Schering Ag | Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen |
| JP2009539793A (ja) * | 2006-06-08 | 2009-11-19 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | 診断及び治療用途のための官能化された固体ポリマーナノ粒子 |
-
2007
- 2007-12-10 DE DE102007059752A patent/DE102007059752A1/de not_active Withdrawn
-
2008
- 2008-12-06 WO PCT/EP2008/010371 patent/WO2009074274A1/de not_active Ceased
- 2008-12-09 TW TW097147937A patent/TW200932220A/zh unknown
- 2008-12-09 UY UY31521A patent/UY31521A1/es not_active Application Discontinuation
- 2008-12-09 PA PA20088806901A patent/PA8806901A1/es unknown
- 2008-12-09 PE PE2008002025A patent/PE20091107A1/es not_active Application Discontinuation
- 2008-12-10 AR ARP080105366A patent/AR069638A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY31521A1 (es) | 2009-08-03 |
| TW200932220A (en) | 2009-08-01 |
| DE102007059752A1 (de) | 2009-06-18 |
| WO2009074274A1 (de) | 2009-06-18 |
| PA8806901A1 (es) | 2009-07-23 |
| AR069638A1 (es) | 2010-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20091107A1 (es) | Nanoparticulas polimericas solidas funcionalizadas que comprenden epotilonas | |
| Murugesan et al. | Chitosan‐based nanocomposites for medical applications | |
| Gowda et al. | Stimuli-responsive microneedles as a transdermal drug delivery system: a demand-supply strategy | |
| Ayoubi‐Joshaghani et al. | Potential applications of advanced nano/hydrogels in biomedicine: static, dynamic, multi‐stage, and bioinspired | |
| Zahid et al. | Leveraging the advancements in functional biomaterials and scaffold fabrication technologies for chronic wound healing applications | |
| Doraiswamy et al. | Two photon induced polymerization of organic–inorganic hybrid biomaterials for microstructured medical devices | |
| Ma et al. | Mesoporous silica as micro/nano-carrier: From passive to active cargo delivery, a mini review | |
| Razatos et al. | Force measurements between bacteria and poly (ethylene glycol)-coated surfaces | |
| Korkmaz et al. | Therapeutic intradermal delivery of tumor necrosis factor-alpha antibodies using tip-loaded dissolvable microneedle arrays | |
| Hou et al. | Microtopographic patterns affect Escherichia coli biofilm formation on poly (dimethylsiloxane) surfaces | |
| EP3548135B1 (en) | Core-shell microneedle devices and uses thereof | |
| AR117389A2 (es) | Composiciones de fenilalaninamoniacoliasa de procariontes y uso de sus composiciones en métodos para tratar cáncer | |
| BRPI0905752A2 (pt) | "muteína de lipocalina da lágrima humana (htlc), molécula de ácido nucléico, célula hospedeira, composição farmacêutica, método para a produção de uma muteína de lipocalina da lágrima humana, método de tratamento de uma doença ou distúrbio e uso de uma mateína de lipocalina da lágrima humana" | |
| Massaro et al. | Multifunctional carrier based on halloysite/laponite hybrid hydrogel for kartogenin delivery | |
| WO2010123945A3 (en) | Silk fibroin hydrogels and uses thereof | |
| Yang et al. | Intra‐articular injection of nanomaterials for the treatment of osteoarthritis: from lubrication function restoration to cell and gene therapy | |
| Barthes et al. | Stretch-induced biodegradation of polyelectrolyte multilayer films for drug release | |
| Chen et al. | Robust, flexible, and bioadhesive free-standing films for the co-delivery of antibiotics and growth factors | |
| Majcher et al. | Applications of hydrogels | |
| Seo et al. | Diatom microbubbler for active biofilm removal in confined spaces | |
| WO2008085556A3 (en) | Surfactant-free nanoparticles for drug delivery | |
| Zhou et al. | Dynamic and wearable electro-responsive hydrogel with robust mechanical properties for drug release | |
| Pepelanova | Tunable hydrogels: introduction to the world of smart materials for biomedical applications | |
| Phoungtawee et al. | Polymers with hemiaminal ether linkages for pH-responsive antibacterial materials | |
| Yu et al. | β-Lactamase responsive supramolecular hydrogels with host–guest self-healing capability |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |